Skip to main content
Premium Trial:

Request an Annual Quote

Natera Sells Evercord Cord Blood Banking Business to CBR

NEW YORK – Natera is selling its Evercord cord blood and tissue banking business to CBR (Cord Blood Registry), a California Cryobank Life Sciences company, the firms said today.

"This divestiture will allow Natera to focus squarely on its core genetic testing business in reproductive health, oncology, and organ transplantation," Natera CEO Steve Chapman said in a statement.

"We look forward to safeguarding these newborn stem cells and allowing the Evercord families to take advantage of future advances in cellular therapies and regenerative medicine," said CCLS CEO Richard Jennings in a statement.

Natera launched the Evercord business in 2017, hoping it would enable it to offer newborn whole-genome screening eventually. The service allows parents to collect and store cord blood and tissue from their newborns and retrieve them later, if needed, for therapeutic use. Last year, Natera said that uptake of the service had been slower than anticipated.

CBR said it will work closely with Natera to ensure a smooth transition for customers and ordering clinics.

Financial details of the sale were not disclosed.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.